The scale of that problem is striking. Autologous fat grafting, in which fat is harvested from one part of the body and reinjected into another, is attractive because the material is biocompatible, easy to obtain, inexpensive, and causes minimal donor-site damage. Yet studies cited by the team indicate that simple fat grafting loses between 20 and 70 percent of its volume, largely because the transplanted tissue is starved of blood supply and suffers mechanical trauma during injection. Without rapid revascularization, adipocytes in the center of the graft suffocate and die, triggering necrosis, resorption, and the need for repeated procedures. Improving graft survival therefore requires not just keeping fat cells alive but encouraging new capillaries to grow into the tissue and prompting resident stem cells to become mature fat cells.

The researchers’ solution hinges on a well-known but powerful chemical reaction. They first oxidized hyaluronic acid with sodium periodate, converting some of its sugar units into aldehyde-bearing molecules, and separately grafted carbohydrazide onto gelatin. When the two modified polymers are mixed in water, the aldehyde groups on the oxidized hyaluronic acid react with the hydrazide groups on the gelatin to form hydrazone bonds, a dynamic covalent linkage produced through a Schiff base reaction. Because these bonds form and break reversibly under mild, body-friendly conditions, the resulting hydrogel is not a brittle solid but a resilient, self-repairing network. Spectroscopic analysis confirmed the chemistry: the aldehyde peak at 1735 wavenumbers vanished from the hydrogel spectrum while a new C=N stretching signal appeared, and nuclear magnetic resonance showed hydrazone proton signatures, verifying successful crosslinking.

After screening formulations at three concentrations and several mixing ratios, the team identified an optimal composition, labeled B1, containing 5 percent Gel-CDH and 2 percent OHA mixed one to one. This formulation gelled in just under 13 seconds, a speed the authors note is close to the roughly 10-second window considered ideal for clinical injectability, since material that sets too slowly can leak away from the target site. Scanning electron microscopy revealed an irregular, porous interior with pores averaging 116 micrometers and porosity near 84 percent, dimensions well suited to oxygen and nutrient exchange and to the survival of fat cells. The hydrogel’s compressive modulus measured 2.18 kilopascals, sitting comfortably within the 0.5 to 25 kilopascal range reported for native human adipose tissue, an important match because cells respond to the stiffness of their surroundings and differentiate best on matrices that mimic the target tissue.

The self-healing behavior is perhaps the most visually compelling property. When the team cut hydrogel samples in half and pressed the pieces back together, the material fused seamlessly within five minutes at room temperature, forming a single cohesive blob that could be lifted with tweezers without breaking. Rheological tests explained why: when the gel was strained beyond a critical threshold of 480 percent, its storage modulus dropped below its loss modulus and the network collapsed into a fluid, but once the strain was released the dynamic hydrazone bonds reformed and the gel recovered its original stiffness. The material also showed classic shear-thinning, meaning it flows easily under the pressure of a syringe and then rapidly regains its solid character once injected. Injected through a standard needle into heart-shaped, triangular, and square molds, the gel set into complete, well-defined shapes, demonstrating that it can conform precisely to the irregular cavities left by tumors or trauma.

Controlling the release of b-FGF was central to the design. Free growth factor is dangerous in excess, with the authors noting that too much b-FGF can cause tissue overgrowth or even tumorigenesis, while a burst release wastes the payload before new vessels can form. Encapsulated in the hydrogel, the growth factor was retained by dynamic crosslinking between its amino groups and the aldehyde groups of the oxidized hyaluronic acid. Release experiments showed a gentle profile: a modest initial phase over three days followed by a plateau, with cumulative release reaching 80 to 90 percent by day seven. The B1 formulation released about 40 percent on the first day and roughly 90 percent by the end of the week, a sustained supply the authors attribute to its larger pores and lower aldehyde content, which eased adsorption of the protein. Hydrogels of this kind, the team notes, can extend the half-life of growth factors and avoid the burst release and rapid proteolysis that plague free injections.

Safety testing produced consistently reassuring results. Rat adipose-derived stem cells cultured with the hydrogel and its precursors maintained viability above 90 percent throughout a week of observation, and by day seven the cells exposed to the full hydrogel actually proliferated slightly faster than untreated controls. Live-dead staining confirmed abundant healthy, spindle-shaped cells, and hemolysis assays showed that none of the materials damaged red blood cells, with hemolysis rates below 1 percent. When the hydrogel was injected under the skin of rats and monitored for three months, ultrasound tracking showed gradual degradation, from about 42 percent at ten days to more than 95 percent by day thirty for the B1 formulation, while histology of the implant site and of the heart, liver, spleen, lungs, and kidneys revealed no inflammation, necrosis, or organ abnormalities. Immunostaining for the inflammatory markers TNF-alpha and CD206 showed no significant differences from saline controls.

The decisive test combined the hydrogel, the growth factor, and autologous fat in living animals. Four groups of rats received subcutaneous injections: hydrogel alone, fat alone, fat in hydrogel, and fat in hydrogel with b-FGF. Four weeks later, the plain fat grafts had shriveled to a retention rate of just 1.92 percent of the original 4-milliliter volume, with histology showing enlarged, hypoxic adipocytes and extensive liquefactive necrosis. Fat embedded in the hydrogel fared far better, retaining 36.67 percent, while the addition of b-FGF pushed retention to 58.33 percent, with the grafts appearing soft, glossy, and threaded with visible surface vessels. Adipocyte diameters in the growth-factor group measured about 70 micrometers, squarely within the 60 to 110 micrometer range of normal mature fat cells, and the adipose tissue area reached nearly 77 percent of the graft, versus 38 percent for fat alone. Fibrosis also fell, dropping to about 15 percent of tissue area by four weeks.

Molecular evidence reinforced the picture. Immunofluorescence for the endothelial markers CD31 and CD34 showed steadily rising vascular density, peaking at roughly 3.8 to 3.9 percent in the growth-factor group at four weeks, significantly above all controls, indicating that new capillaries had grown both around and into the implant. Staining for PPAR-gamma, a master transcription factor that initiates fat-cell differentiation, and for Perilipin-1, the gold-standard marker of mature lipid-filled adipocytes, both climbed over time and were highest in the composite group. Reverse transcription PCR likewise showed marked upregulation of the angiogenic gene CD31 and the adipogenic genes AP-2, C/EBP-beta, and PPAR-gamma. Together these data trace a coherent sequence in which sustained b-FGF delivery first drives vessel formation and then supports the maturation of functional fat tissue, exactly the coupling the designers intended.

The authors are candid that longer follow-up is needed, noting that observation periods of eight to twelve weeks would establish whether the early gains translate into durable adipose regeneration, and the work so far rests on rat models rather than human trials. Even so, the study offers a compelling template: a hydrogel assembled in seconds from FDA-familiar building blocks, matched mechanically to native fat, capable of healing itself and conforming to any defect shape, and able to meter out a potent growth factor over a week. If the approach survives longer-term and larger-animal testing, it could shift fat grafting from a procedure plagued by unpredictable resorption toward a controlled regenerative therapy for breast reconstruction, facial restoration, and the many patients whose soft tissue defects currently outpace what surgery alone can rebuild.

Subject of Research: An injectable self-healing gelatin-hyaluronic acid hydrogel with slow-release b-FGF for adipose tissue regeneration

Article Title: Injectable self-healing polysaccharide hydrogel with slow-release b-FGF for adipose tissue regeneration

Article References: Wu, S., Shu, W., Zhu, X., Chen, Y. M., Liu, Z., Wang, Y., Song, H., Xiao, D., Zhai, C., Jiang, N., & Li, J. (2026). Injectable self-healing polysaccharide hydrogel with slow-release b-FGF for adipose tissue regeneration. Materials Today Bio, 41, Article 103739. https://doi.org/10.1016/j.mtbio.2026.103739

Image Credits: AI Generated

DOI: Not provided

Keywords: hydrogel, adipose tissue regeneration, b-FGF, fat grafting, tissue engineering, hyaluronic acid, gelatin, self-healing materials, drug delivery, angiogenesis, adipogenesis, soft tissue repair

The research team, led by Katerina Green and Deanna Menapace of the Department of Otolaryngology-Head and Neck Surgery, together with colleagues from dermatology and the Mayo Clinic Alix School of Medicine, conducted a systematic PubMed search that identified 19 published studies documenting adverse events associated with regenerative therapeutics in facial plastic surgery. They supplemented this literature analysis with a retrospective chart review of six patients treated at their own institution who experienced complications from these procedures. Their findings paint a detailed picture of what can go wrong when biologically active materials are injected into the highly vascular landscape of the face.

The technical appeal of these therapies is easy to understand. Platelet-rich plasma, or PRP, is derived from a patient’s own blood, which is centrifuged to concentrate platelets and the growth factors they carry. When injected into the skin or scalp, these factors stimulate angiogenesis and collagen synthesis, promoting tissue repair and regeneration. Nanofat, meanwhile, is produced by mechanically emulsifying harvested fat until mature adipocytes are broken down, leaving behind the stromal vascular fraction and adipose-derived stem cells with regenerative properties. Exosomes, tiny extracellular vesicles packed with signaling molecules, represent the newest frontier, marketed for anti-inflammatory and collagen-stimulating effects on skin texture and pore size.

Yet the review reveals that the most devastating complications share a common mechanism: vascular embolism. When injectable material enters an artery, it can travel retrograde into the ophthalmic artery and its branches, occluding blood supply to the retina or brain. The literature documents eight cases of vision loss following PRP injection, six of them permanent. Seven of these occurred after injections into the glabella, the region between the eyebrows where the supratrochlear and supraorbital arteries lie in close proximity to the ophthalmic system. Patients reported losing vision almost immediately, and central retinal artery occlusion is treatable only within an approximately four-hour window, a deadline frequently missed when injections occur in non-hospital settings.

Autologous fat grafting carries even greater documented risk. A systematic review cited in the paper identified 61 cases of arterial embolism after facial fat injection, including six deaths. In one reported case, an 18-year-old woman developed hemiplegia and loss of consciousness 24 hours after temporal fat injection; imaging revealed an infarction of the right external carotid artery caused by fat embolism, and despite decompressive craniotomy she died of central respiratory failure. In another, fat injected into the nasolabial fold entered the dorsal nasal artery and migrated to the ophthalmic artery, causing irreversible blindness. By contrast, nanofat injections appear far gentler: a review of 36 patients treated for periorbital dark circles found only transient bruising and mild edema, both resolving within days.

The Mayo Clinic cases add valuable new detail to this risk map. The first describes a 47-year-old woman who developed painful reactive lymphadenopathy the night after scalp PRP injections for hair loss, requiring emergency evaluation, CT imaging, and antibiotics before symptoms resolved. The authors suggest this may establish PRP alone, independent of microneedling with which it has previously been combined, as a trigger for lymph node swelling, possibly through local trauma or reaction to concentrated growth factors. The second case is the first of its kind: a 51-year-old woman developed facial tingling, numbness, and arm heaviness minutes after scalp PRP, prompting a full stroke workup. When imaging excluded ischemia, clinicians concluded she had experienced an acephalgic migraine with aura triggered by the procedure, a side effect never previously associated with PRP that may be relevant when injections follow trigeminal nerve distributions.

Three further institutional cases involved fat and nanofat. One patient who received temporal microfat and nanofat mixed with PRP developed delayed fat necrosis seven months after surgery, with a fluid collection that required serial aspiration and MRI confirmation, ultimately leaving the aesthetic result suboptimal. Two other patients developed nodular swelling after periorbital nanofat grafting; in one, intralesional triamcinolone resolved the nodules, while in the other persistent fullness required surgical excision, illustrating that treatment responses vary and clinical flexibility is essential. A sixth patient, treated with a topical human-derived exosome product after laser resurfacing, developed facial swelling and blistering consistent with suspected contact dermatitis, believed to be the first reported complication of topical exosome therapy in the United States.

The exosome literature emerging internationally is more concerning. Injectable exosome products are not approved by the US Food and Drug Administration, and their composition varies enormously between manufacturers depending on source material, isolation methods, and processing. Reported complications include granuloma formation, hypersensitivity reactions, persistent nodular lesions refractory to corticosteroids, and painful cutaneous necrosis that responded poorly even to carbon dioxide laser treatment. Notably, many of the severe reactions occurred after injections administered at private, non-hospital clinics, whereas a hospital-based retrospective series of 40 patients receiving exosome skin boosters with microneedling reported only expected erythema and edema resolving within 48 hours.

The authors emphasize that an underappreciated contributor to these complications is the profound heterogeneity of the products themselves. PRP preparation protocols differ in centrifugation speed, duration, and technique, producing wide variation in platelet concentration and cellular composition. Nanofat quality depends on harvesting location, instrumentation, and the number of emulsification passes. Exosome formulations differ in origin and purity. This variability limits reproducibility across studies and clinics, complicates comparisons of safety data, and means that two patients receiving nominally identical treatments may receive biologically distinct products. Regulatory frameworks have struggled to keep pace: the FDA regulates only minimally manipulated, homologous-use human cell products under 21 CFR 1271, PRP largely escapes the HCT/P framework as an autologous blood product, and recent state legislation such as a 2025 Florida law has expanded physician discretion to offer certain non-FDA-approved regenerative therapies.

Prevention, the authors argue, remains the most effective strategy because treatments for established embolic complications are notoriously unreliable. Ocular massage, anterior chamber paracentesis, intraocular pressure-lowering agents, hyaluronidase, hyperbaric oxygen, and intra-arterial thrombolysis have all been attempted for injection-related blindness, and none has proven consistently effective. Recommended safeguards include mapping vascular anatomy before procedures, avoiding bolus injections and previously traumatized sites, using small cannulas with low injection pressure and volume, employing ultrasound guidance where available, and maintaining an emergency protocol for immediate injection cessation with rapid referral to ophthalmology or emergency services. The researchers also call for candid discussion of risks in the literature, noting that favorable safety profiles and underreporting have combined to leave patients and providers underinformed. Their central message is measured rather than alarmist: PRP, fat grafting, and exosome therapies offer real aesthetic benefit when used with stewardship, but providers must understand each modality’s mechanism, screen patients for cardiovascular, hematological, and immunological risk factors, and prepare for the rare but catastrophic complications that these otherwise promising biologics can produce.

Subject of Research: Complications of regenerative medicine therapies, including platelet-rich plasma, fat and nanofat grafting, and exosomes, in facial plastic surgery

Article Title: Complications of regenerative therapeutics in facial plastic surgery: a case series and review of the literature

Article References: Green, K., Pascal, G. J., Tolaymat, L., Bruce, A., & Menapace, D. (2026). Complications of regenerative therapeutics in facial plastic surgery: a case series and review of the literature. BMC Plastic and Reconstructive Surgery, 2(1), Article 19. https://doi.org/10.1186/s44452-026-00032-w

Image Credits: AI Generated

DOI: 10.1186/s44452-026-00032-w

Keywords: regenerative medicine, facial plastic surgery, platelet-rich plasma, fat grafting, nanofat, exosomes, blindness, embolism, aesthetic medicine, complications, PRP, cosmetic injections